title: [Auditory assessment in a protocol of concurrent carboplatin and irradiation use in fractionated therapy].
abstract: Possible ototoxicity related with a hyperfractionated concurrent chemo-radiation schedule was studied in 36 patients with head and neck cancer. The schedule consisted of two daily fractions, each consisting of 5 mg/m2 of carboplatin plus 115 cGy. Therapy was given 5 days a week for 7 weeks up to a total dose of 700 mg carboplatin and 8050 cGy. Tonal audiograms and superliminal tests were carried out before treatment, at conclusion, six months post-treatment, and every year thereafter. After a mean follow-up of 18 months (maximum 30 months), no treatment-related sensorineural hearing loss was observed. However, recruitment disappeared in post-treatment superliminal tests in 37% of patients who presented sensorineural deafness with recruitment, although it reappeared in audiograms recorded six months later. We attributed this to transient demyelinization. After treatment, a previous tympanosclerosis reactivated in 1 case and effusive otitis media occurred in 8 patients. Previous effusive otitis media disappeared in 1 patient (nasopharyngeal tumor).
authors.affiliation: Hospital Nuestra Señora de la Candelaria, Santa Cruz de Tenerife.
authors.forename: J L
authors.initials: JL
authors.lastname: De Serdio
authors.forename: A
authors.initials: A
authors.lastname: Villar
authors.forename: B F
authors.initials: BF
authors.lastname: Halawa
authors.forename: I
authors.initials: I
authors.lastname: González-Castro
authors.forename: I E
authors.initials: IE
authors.lastname: Alvarez
authors.forename: J J
authors.initials: JJ
authors.lastname: Artazkoz
authors.forename: D
authors.initials: D
authors.lastname: López-Aguado
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001301:Audiometry, Pure-Tone / Q000379:methods*; D016190:Carboplatin / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000150:complications / Q000188:drug therapy* / Q000532:radiotherapy*; D002985:Clinical Protocols; D003131:Combined Modality Therapy; D019583:Dose Fractionation, Radiation; D005260:Female; D006258:Head and Neck Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000532:radiotherapy*; D006319:Hearing Loss, Sensorineural / Q000175:diagnosis* / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged
chemical_list: D000970:Antineoplastic Agents; D016190:Carboplatin
vernacular_title: Valoración auditiva en un protocolo con aplicación concomitante de carboplatino e irradiación dentro de cada fracción terapéutica.